US FDA approves tepotinib for treatment of adults with metastatic non-small cell lung cancer who have a MET exon 14 skipping alteration

The approval was based on data from the Phase II VISION trial, in which tepotinib monotherapy was associated with an overall response rate of 43% among both treatment-naïve and previously treated patients.

Source:

Biospace Inc.